U.S. Labor Department reports website issues ahead of jobs data release
Investing.com -- SINTX Technologies, Inc. (NASDAQ:SINT) stock surged 29% after the company published a peer-reviewed study demonstrating its silicon nitride material’s effectiveness against multiple virus strains, including SARS-CoV-2 and MERS-CoV.
The study, conducted with Virginia Tech researchers, showed that direct contact with SINTX’s alpha-phase silicon nitride reduced infectious SARS-CoV-2 titers by up to 99.97% within 10 minutes, with complete inactivation observed after 30 minutes. The material also demonstrated 97% inactivation when embedded in textile fabric commonly used in medical devices and PPE products.
SINTX’s silicon nitride technology releases reactive nitrogen species such as ammonia and nitric oxide that damage viral RNA and proteins without harming surrounding tissue, giving it advantages over traditional antimicrobial materials like copper, silver, or zinc, which may raise toxicity concerns.
"This study confirms that silicon nitride is much more than a high-performance implant material—it’s a safe, effective, and broad-spectrum antiviral platform," said Dr. Ryan Bock, Chief Technology Officer of SINTX Technologies and co-author of the study.
The company is positioning its proprietary material for use in various infection-prevention applications, including wound dressings, surgical sutures, face masks, hospital linens, and HEPA filters. SINTX is the only U.S.-based FDA-cleared and ISO-certified silicon nitride manufacturer.
This development marks a strategic shift as SINTX transitions from a single-product orthopedic implant manufacturer to a platform technology company targeting the global infection-prevention market, which is projected to exceed $230 billion by 2032.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.